Showing results (351-360 of 679) with videos related to
Sort By:
Pageof 68
Plos One|February 7, 2017
Soluble human leukocyte antigen -G during pregnancy and infancy in Benin: Mother/child resemblance and association with the risk of malaria infection and low birth weightTania C d'Almeida, Ibrahim Sadissou, Jacqueline Milet, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 31, 2013
Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trialsPieter Sonneveld, Hartmut Goldschmidt, Laura Rosiñol, et al.Plos One|November 9, 2013
Polymorphic sites at the 3' untranslated region of the HLA-G gene are associated with differential hla-g soluble levels in the Brazilian and French populationGustavo Martelli-Palomino, Joao A Pancotto, Yara C Muniz, et al.Cancer Medicine|February 29, 2020
Once-weekly (70 mg/m2 ) vs twice-weekly (56 mg/m2 ) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION-1 trialsPhilippe Moreau, Keith A Stewart, Meletios Dimopoulos, et al.British Journal of Haematology|November 9, 2018
A novel complete blood count-based score to screen for myelodysplastic syndrome in cytopenic patientsRobin Boutault, Pierre Peterlin, Marouane Boubaya, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 3, 2020
Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple MyelomaMax S Topp, Johannes Duell, Gerhard Zugmaier, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 21, 2020
Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome GroupMehmet Kemal Samur, Anil Aktas Samur, Mariateresa Fulciniti, et al.Haematologica|June 22, 2014
Results from a clofarabine-busulfan-containing, reduced-toxicity conditioning regimen prior to allogeneic stem cell transplantation: the phase 2 prospective CLORIC trialPatrice Chevallier, Myriam Labopin, Gérard Socié, et al.Blood Cancer Journal|February 2, 2024
GPRC5D as a novel target for the treatment of multiple myeloma: a narrative reviewPaula Rodriguez-Otero, Niels W C J van de Donk, Kodandaram Pillarisetti, et al.Blood|January 7, 2006
Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myelomaFrederic Garban, Michel Attal, Mauricette Michallet, et al.Pageof 68